drugset / Trial / NCT01281202
Vigabatrin for the Treatment of Cocaine Dependency
Phase 2/3
Completed
207 enrolled
Catalyst Pharmaceuticals, Inc.
National Institute on Drug Abuse (NIDA) · collabVA Office of Research and Development · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The objective of this 26-28 week study is to demonstrate that the rate of cocaine dependent subjects treated with CPP-109 vigabatrin in addition to counseling, who completely stop use of cocaine in the last 2 weeks of the study's Treatment Phase (Weeks 8 and 9) will be higher than seen in subjects treated with placebo in addition to counseling.
Timeline
- Start
- 2011-01
- Primary completion
- 2012-10
- Completion
- 2012-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Vigabatrin | Small molecule | 1500 mg | — |